Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Oleuropeic acid 8-O-glucoside

$655

  • Brand : BIOFRON

  • Catalogue Number : AV-B02894

  • Specification : 96%

  • CAS number : 865887-46-3

  • Formula : C16H26O8

  • Molecular Weight : 346.37

  • PUBCHEM ID : 11152176

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B02894

Analysis Method

HPLC,NMR,MS

Specification

96%

Storage

2-8°C

Molecular Weight

346.37

Appearance

Powder

Botanical Source

Structure Type

Monoterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC(C)(C1CCC(=CC1)C(=O)O)OC2C(C(C(C(O2)CO)O)O)O

Synonyms

1-Cyclohexene-1-carboxylic acid, 4-[1-(β-D-glucopyranosyloxy)-1-methylethyl]-, (4S)-/(4S)-4-[2-(β-D-Glucopyranosyloxy)-2-propanyl]-1-cyclohexene-1-carboxylic acid

IUPAC Name

(4S)-4-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]cyclohexene-1-carboxylic acid

Applications

Density

1.4±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

207.9±23.6 °C

Boiling Point

575.0±50.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C16H26O8/c1-16(2,9-5-3-8(4-6-9)14(21)22)24-15-13(20)12(19)11(18)10(7-17)23-15/h3,9-13,15,17-20H,4-7H2,1-2H3,(H,21,22)/t9-,10-,11-,12+,13-,15+/m1/s1

InChl Key

RQEWNDZNKBUWDH-LREAXHOUSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:865887-46-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30165561

Abstract

Few studies have assessed the risk of adverse pregnancy outcomes in women with multiple sclerosis (MS). We used 2 large US administrative databases, the Truven Health MarketScan Database (2011-2015; Truven Health Analytics Inc., Ann Arbor, Michigan) and the Nationwide Inpatient Sample (2007-2011), to identify delivery cohorts. MS and pregnancy outcomes (infections, cesarean delivery, preterm delivery, poor fetal growth, preeclampsia, chorioamnionitis, postpartum hemorrhage, stillbirth, and infant malformations) were identified during pregnancy and at delivery. We calculated adjusted risk ratios according to MS status and relapse(s) in the year before delivery. Among over 5 million pregnancies, we identified 3,875 pregnancies in women with MS. Women with MS had an increased risk of infections during pregnancy (Truven Health: adjusted risk ratio (aRR) = 1.22, 95% confidence interval (CI): 1.16, 1.27) and preterm delivery (Truven Health: aRR = 1.19 (95% CI: 1.04, 1.35); Nationwide Inpatient Sample: aRR = 1.30 (95% CI: 1.16, 1.44)). The risks of other outcomes were similar for women with and without MS. In the Truven Health database, risk ratios for the pregnancy outcomes in women experiencing relapses versus those without relapses were between 0.9 and 1.4, and confidence intervals overlapped the null. Overall, women with MS had an increased risk of infections and preterm delivery; however, their risks for other adverse pregnancy outcomes were not elevated. Disease activity before delivery was not a strong predictor of outcomes.

KEYWORDS

administrative claims, multiple sclerosis, pregnancy

Title

Pregnancy Outcomes in Women With Multiple Sclerosis

Author

Sarah C MacDonald,1 Thomas F McElrath,2 and Sonia Hernandez-Diaz1

Publish date

2019 Jan